BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 28289089)

  • 1. Molecular Pathways: Oncologic Pathways and Their Role in T-cell Exclusion and Immune Evasion-A New Role for the AXL Receptor Tyrosine Kinase.
    Aguilera TA; Giaccia AJ
    Clin Cancer Res; 2017 Jun; 23(12):2928-2933. PubMed ID: 28289089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer.
    Hughes PE; Caenepeel S; Wu LC
    Trends Immunol; 2016 Jul; 37(7):462-476. PubMed ID: 27216414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coinhibitory Pathways in Immunotherapy for Cancer.
    Baumeister SH; Freeman GJ; Dranoff G; Sharpe AH
    Annu Rev Immunol; 2016 May; 34():539-73. PubMed ID: 26927206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy: Beyond Anti-PD-1 and Anti-PD-L1 Therapies.
    Antonia SJ; Vansteenkiste JF; Moon E
    Am Soc Clin Oncol Educ Book; 2016; 35():e450-8. PubMed ID: 27249753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.
    Hargadon KM; Johnson CE; Williams CJ
    Int Immunopharmacol; 2018 Sep; 62():29-39. PubMed ID: 29990692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
    Herzberg B; Campo MJ; Gainor JF
    Oncologist; 2017 Jan; 22(1):81-88. PubMed ID: 27534574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy.
    Picarda E; Ohaegbulam KC; Zang X
    Clin Cancer Res; 2016 Jul; 22(14):3425-3431. PubMed ID: 27208063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune Evasion Mechanism and AXL.
    Son HY; Jeong HK
    Front Oncol; 2021; 11():756225. PubMed ID: 34778071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The present status and future prospects of peptide-based cancer vaccines.
    Hirayama M; Nishimura Y
    Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoantigen heterogeneity: a key driver of immune response and sensitivity to immune checkpoint blockade?
    Furness AJ; Quezada SA; Peggs KS
    Immunotherapy; 2016 Jun; 8(7):763-6. PubMed ID: 27349975
    [No Abstract]   [Full Text] [Related]  

  • 11. PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors.
    Seifert AM; Zeng S; Zhang JQ; Kim TS; Cohen NA; Beckman MJ; Medina BD; Maltbaek JH; Loo JK; Crawley MH; Rossi F; Besmer P; Antonescu CR; DeMatteo RP
    Clin Cancer Res; 2017 Jan; 23(2):454-465. PubMed ID: 27470968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges.
    Kyi C; Postow MA
    Immunotherapy; 2016 Jun; 8(7):821-37. PubMed ID: 27349981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The future of immune checkpoint cancer therapy after PD-1 and CTLA-4.
    Hahn AW; Gill DM; Pal SK; Agarwal N
    Immunotherapy; 2017 Jun; 9(8):681-692. PubMed ID: 28653573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.
    Philips GK; Atkins M
    Int Immunol; 2015 Jan; 27(1):39-46. PubMed ID: 25323844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
    Sweis RF; Galsky MD
    Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune checkpoint inhibition in ovarian cancer.
    Hamanishi J; Mandai M; Konishi I
    Int Immunol; 2016 Jul; 28(7):339-48. PubMed ID: 27055470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting T Cell Co-receptors for Cancer Therapy.
    Callahan MK; Postow MA; Wolchok JD
    Immunity; 2016 May; 44(5):1069-78. PubMed ID: 27192570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New checkpoints in cancer immunotherapy.
    Ni L; Dong C
    Immunol Rev; 2017 Mar; 276(1):52-65. PubMed ID: 28258699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Introduction: Cancer Immunology Special Issue-Immunotherapy.
    Kawakami Y
    Int Immunol; 2016 Jul; 28(7):317. PubMed ID: 27313100
    [No Abstract]   [Full Text] [Related]  

  • 20. Part I: Checkpoint inhibitors in cancer therapy.
    Daud AI
    Immunotherapy; 2016 Jun; 8(6):675-6. PubMed ID: 27197535
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.